Docetaxel (CAS 114977-28-5) is a high-purity, pharmaceutical-grade antineoplastic agent derived from taxane extracts and refined via advanced purification technology, fully complying with USP and EP quality standards. Its molecular structure is optimized to stabilize microtubules, inhibiting tumor cell division and proliferation—targeting a broad range of solid tumors with high efficacy. Produced with strict control over residual solvents and impurities (total impurities ≤0.1%), each batch undergoes rigorous potency and stability testing, ensuring consistent therapeutic performance for oncology drug formulation.
This iconic taxane antineoplastic stands out for its proven clinical efficacy in treating breast cancer, non-small cell lung cancer, prostate cancer, and other malignancies. Unlike conventional chemotherapeutics, it exhibits enhanced tumor cell selectivity, reducing unnecessary damage to normal cells cells while improving treatment outcomes. Its flexible administration routes (intravenous injection as the primary form) and compatibility with combination therapy make it a cornerstone of modern oncology treatment regimens.
Docetaxel (CAS 114977-28-5) caters to professional needs: pharmaceutical manufacturers developing targeted chemotherapy drugs, research institutions studying tumor cell biology, and biotech firms advancing oncology therapies. Its clinical gold-standard status, pharmaceutical-grade purity, and broad antitumor spectrum make it a top choice for buyers prioritizing reliability and therapeutic value. Whether for large-scale commercial production or preclinical research, this taxane antineoplastic meets the stringent demands of the global pharmaceutical and oncology sectors.
